M. Byakhov

Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

J. Baselga, W. Eiermann, V. Semiglazov, 2008 .

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

J. Baselga, W. Eiermann, A. Lluch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

J. Baselga, M. Climent, W. Eiermann, 2014, The Lancet. Oncology.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

J. Baselga, V. Semiglazov, A. Manikhas, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER 2-positive metastatic breast cancer

J. Baselga, V. Semiglazov, A. Manikhas, 2014 .

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

J. Baselga, W. Eiermann, A. Lluch, 2005, Clinical Cancer Research.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

C. Hudis, J. Baselga, V. Semiglazov, 2014 .

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.